Home » Archive by Category

Syndication

UC San Diego’s Brown Briefs Congress on Brain Development, Substance Use in Young

November 20, 2014 – 7:00 am | Edit Post

Sandra A. Brown, vice chancellor for research at UC San Diego, was a featured speaker at an October Congressional Briefing in Washington, D.C., where she shared important findings on adolescent neurodevelopment with other scientists and national leaders.

ViaCyte to Present at 26th Annual Piper Jaffray Healthcare Conference

November 20, 2014 – 7:00 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference as follows:

Conference:

Tuesday, December 2, 2014

Time:

4:10 p.m. EST

Location:

The New York Palace, New York City

Dr. Laikind will review recent progress with the company’s VC-01™ islet replacement product candidate for the treatment of type 1 diabetes, which recently entered clinical phase testing.  A Phase 1/2 trial to assess safety, tolerability, and efficacy of the product in human subjects with diabetes was launched in September 2014, and the first implant was announced in October 2014. 

The presentation will be webcast live at the aforementioned time, and archived for viewing 90 days thereafter, via the Company’s website at www.viacyte.com, under the News and Events Section.

About ViaCyte  ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.  ViaCyte’s lead product candidate, the VC-01 combination product, is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  VC-01 is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications. 

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine and JDRF. 

Logo – http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
SOURCE ViaCyte

ViaCyte to Present at 26th Annual Piper Jaffray Healthcare Conference

November 20, 2014 – 7:00 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference as follows:

Conference:

Tuesday, December 2, 2014

Time:

4:10 p.m. EST

Location:

The New York Palace, New York City

Dr. Laikind will review recent progress with the company’s VC-01™ islet replacement product candidate for the treatment of type 1 diabetes, which recently entered clinical phase testing.  A Phase 1/2 trial to assess safety, tolerability, and efficacy of the product in human subjects with diabetes was launched in September 2014, and the first implant was announced in October 2014. 

The presentation will be webcast live at the aforementioned time, and archived for viewing 90 days thereafter, via the Company’s website at www.viacyte.com, under the News and Events Section.

About ViaCyte  ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.  ViaCyte’s lead product candidate, the VC-01 combination product, is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  VC-01 is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications. 

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine and JDRF. 

Logo – http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
SOURCE ViaCyte

ViaCyte to Present at 26th Annual Piper Jaffray Healthcare Conference

November 20, 2014 – 7:00 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference as follows:

Conference:

Tuesday, December 2, 2014

Time:

4:10 p.m. EST

Location:

The New York Palace, New York City

Dr. Laikind will review recent progress with the company’s VC-01™ islet replacement product candidate for the treatment of type 1 diabetes, which recently entered clinical phase testing.  A Phase 1/2 trial to assess safety, tolerability, and efficacy of the product in human subjects with diabetes was launched in September 2014, and the first implant was announced in October 2014. 

The presentation will be webcast live at the aforementioned time, and archived for viewing 90 days thereafter, via the Company’s website at www.viacyte.com, under the News and Events Section.

About ViaCyte  ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.  ViaCyte’s lead product candidate, the VC-01 combination product, is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  VC-01 is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications. 

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine and JDRF. 

Logo – http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
SOURCE ViaCyte

Building the Future of Health Care

November 20, 2014 – 7:00 am | Edit Post

Committed to fostering the future of health care in San Diego, more than 1,000 donors have contributed $131 million to UC San Diego’s Jacobs Medical Center. Included in the total are gifts that matched a donation of $25 million, meeting the Challenge goal of the initiative. Today, the campus announced that the Challenge donation, originally anonymous, was made by Joan and Irwin Jacobs. They provided a $75 million lead gift for the new facility in 2010; with the Challenge gift, that brings their contributions to the Jacobs Medical Center to a total of $100 million.

Bioprocess Technician, Downstream Manufacturing – Genentech – Oceanside, CA

November 20, 2014 – 6:18 am | Edit Post

Biotech certificate from approved program. Degree in Life Sciences or Engineering and 3 years experience, or Associate degree and 5 years experience, or High…
From Genentech – 21 Nov 2014 08:37:58 GMT
– View all Oceanside jobs

Organovo to Present at the 26th Annual Piper Jaffray Healthcare Conference

November 20, 2014 – 6:05 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ – Organovo Holdings, Inc. (NYSE MKT: ONVO) (“Organovo”), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has been invited to present at the 26th Annual Piper Jaffray Healthcare Conference, which will be held in New York December 2-3, 2014.

Organovo’s Chairman and Chief Executive Officer, Keith Murphy, will be presenting on Tuesday, December 2, at 4:30pm ET.

The goal of Piper Jaffray’s 26th Annual Healthcare Conference is to bring together key industry executives, investors and Piper professionals to provide multiple perspectives, investigate critical trends and identify the leaders in the markets that are driving our economy.  The conference will be held at The New York Palace Hotel, 455 Madison Avenue, New York, NY 10022.

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company recently launched its initial product of the planned exVive3DTM portfolio offering, a 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing. Additional products, including a 3D Kidney Model, are in development with anticipated release for use in the latter half of calendar year 2016. Furthermore, the company actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the market acceptance of the Company’s products; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed with the SEC on November 7, 2014, as well as our other filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
SOURCE Organovo Holdings, Inc.

Research Associate/Sr. Research Associate, Product Development – Synthetic Genomics, Inc. – La Jolla, CA

November 19, 2014 – 9:23 pm | Edit Post

Degree in Molecular Biology, Biochemistry, Microbiology, Biotechnology or related discipline, or a BS degree with 2 year experience….
From Synthetic Genomics, Inc. – 20 Nov 2014 07:06:15 GMT
– View all La Jolla jobs

Sr New Product Transfer Scientist – Illumina, Inc. – San Diego, CA

November 19, 2014 – 6:44 pm | Edit Post

They are also responsible for managing the development and execution of the support strategies for new products….
From Illumina, Inc. – 20 Nov 2014 01:44:03 GMT
– View all San Diego jobs

HTS Automation Research Associate

November 19, 2014 – 6:34 pm | Edit Post

Top Three Skills:
liquid handling, troubleshooting assays and equipment
Job Description:
Will join a team that focuses on mass-spec based platforms to discover, validate and identify protein-based biomarkers.
As a key contributor in the successfu [...]